FXR or TGR5 modulators for NASH and T2D (obeticholic acid for FXR, as we have discussed; TGR5 agonists could, in theory, increase GLP-1 levels and reduce inflammation but need to avoid gallbladder side effects, as TGR5 can relax the gallbladder sphincter) [153,281]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.